Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.
Lead Product(s): KCC2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kerry Murphy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 28, 2020